Resources

Prokarium appoints Ibs Mahmood as Chief Executive Officer

Oxford-based techbio startup Scripta Therapeutics emerges from stealth by announcing a $12 million seed round to upend conventional approaches to drug discovery. Scripta combines AI, imaging, and patient-derived models to create and modulate disease maps based on transcriptional networks, building a new biology-first paradigm to decode and undo the programs that drive disease. The round is led jointly by Oxford Science Enterprises (OSE) and Apollo Health Ventures, with further investment from AlbionVC, YZR Capital, and Parkwalk Advisors, and support from Oxford University Innovation.

PIR International recently partnered with a PE-backed pharmaceutical services company in appointing a Chief Growth Officer.

LinkGevity's first-in-class Anti-Necrotic drug was featured in the Sunday Express this week. The article highlights the transformative potential of targeting necrosis- a long-overlooked driver of age-related degeneration.

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its Amperia™ assay portfolio with the launch of its Tagged Protein Quantification Kit | His-tag and Tagged Protein Sensor | His-tag Quantification. The novel assay, developed with GenScript’s THE™ His Tag Monoclonal Antibodies, provides researchers with a ready-to-use solution for rapid, reliable measurement of His-tagged proteins. This launch marks a significant milestone in extending Amperia, beyond antibody and AAV assays, into the wider field of recombinant protein analysis, enabling researchers to generate high-quality data more quickly and dependably across expression, optimisation and development workflows.

The Medical Research Council, Wellcome Trust, and Innovate UK have today announced a major new £15.9m initiative to enable the development of advanced, specific and highly reproducible human-based in vitro models of disease, to make them widely available to researchers in academia and industry.

MyAmici, a leading provider of LabOps solutions for biotech and life science organisations, is pleased to announce its strategic entry into the Swiss market through a partnership with Kisco Pharma Outsourcing Solutions. This collaboration marks a significant milestone in MyAmici’s European expansion and brings together two complementary organisations committed to empowering scientific innovation.

BIA’s influence and connect were out in force last week – grasping a timely opportunity to get our key Autumn Budget asks across impactfully to the Chancellor with the clear backing of over 200 member CEOs, and putting on a dynamic, pro-innovation Future of UK Regulation conference, featuring MHRA and NICE CEOs amongst other key stakeholders.

Brainomix earned top recognition in the Science category for its innovative approach to improving outcomes for patients affected by cardiovascular disease and stroke.

In this blog, Chris Sadler, Development Lead at Astrea Bioseparations Ltd, explores how combining multiple interaction mechanisms in chromatography can unlock new, cost-effective solutions for complex downstream challenges.

Worthwhile investments can be hard to recognise when discussing sustainability initiatives. Let's take a look at five with short payback periods.

​​​​​​​LinkGevity and Delta Biosciences, UAB, a Lithuanian pharmaceutical stability specialist, have been awarded funding from the UK Space Agency to prepare LinkGevity’s pioneering Anti-Necrotic therapeutic for deployment in space.

PIR International was delighted to partner with Slingshot Therapeutics on the appointment of Bobby Soni as Chief Business Officer.

Matt Evans and Liz Mercer are the duo behind ExpertLeader — a purpose-led joint venture dedicated to building leadership excellence in the UK life sciences sector. Their tailored programme is helping leaders grow with confidence, strengthen resilience, and make science work smarter for business success. In this member spotlight, they share more about their new venture and how they aim to create the life science leaders of the future.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Vicore Pharma Holding AB (STO: VICO) and is pleased to announce the placement of Katrine Husum as R&D Senior Project Director.

In its latest annual review, the CGT Catapult demonstrates how it is uniquely positioned to deliver critical advances in the cell and gene therapy industry, from driving forward the industry’s productivity for the economy to improving patient outcomes.

As discussion around the Autumn Budget heats up, BIA is leading a unified call to the Chancellor to back the science, the entrepreneurs and the life sciences industry that can fuel transformational growth for the UK economy. Our sector letter highlights key growth levers and indeed the barriers that hold the sector back in already challenging global conditions. 

AAVantgarde's Stargardt disease and Usher syndrome Ib programmes address the root genetic causes of devastating conditions and offer hope of improvement to patients and families living with progressive vision loss.

LinkGevity featured in Financial Times 5-part global series on Longevity companies. The article highlights how LinkGevity’s pioneering work on Anti-Necrotic technology is opening new frontiers in medicine, with potential for systemic healthspan regeneration.